{"name":"South China Children's Leukemia Group","slug":"south-china-children-s-leukemia-group","ticker":"","exchange":"","domain":"","description":"South China Children's Leukemia Group is a specialized pharmaceutical organization focused on the treatment of pediatric leukemia, offering a range of marketed drugs to improve patient outcomes.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"6MP","genericName":"6MP","slug":"6mp","indication":"Acute lymphoblastic leukemia (ALL)","status":"marketed"},{"name":"ATO","genericName":"ATO","slug":"ato","indication":"Acute promyelocytic leukemia (APL), including newly diagnosed and relapsed/refractory disease","status":"marketed"},{"name":"MTX","genericName":"MTX","slug":"mtx","indication":"Acute lymphoblastic leukemia (ALL) in children","status":"marketed"},{"name":"ATRA","genericName":"ATRA","slug":"atra","indication":"Acute promyelocytic leukemia (APL)","status":"marketed"},{"name":"RIF","genericName":"RIF","slug":"rif","indication":"Infection prophylaxis and treatment in pediatric leukemia patients","status":"marketed"}]}],"pipeline":[{"name":"6MP","genericName":"6MP","slug":"6mp","phase":"marketed","mechanism":"6MP (6-mercaptopurine) is a purine analog that inhibits nucleotide synthesis and DNA replication, leading to cell death in rapidly dividing cells.","indications":["Acute lymphoblastic leukemia (ALL)","Acute myeloid leukemia (AML)","Chronic myeloid leukemia (CML)"],"catalyst":""},{"name":"ATO","genericName":"ATO","slug":"ato","phase":"marketed","mechanism":"Arsenic trioxide induces differentiation and apoptosis of leukemic cells, particularly in acute promyelocytic leukemia.","indications":["Acute promyelocytic leukemia (APL), including newly diagnosed and relapsed/refractory disease"],"catalyst":""},{"name":"MTX","genericName":"MTX","slug":"mtx","phase":"marketed","mechanism":"MTX (methotrexate) inhibits dihydrofolate reductase, blocking the synthesis of purines and pyrimidines required for DNA replication and cell division.","indications":["Acute lymphoblastic leukemia (ALL) in children","Acute myeloid leukemia (AML)","Lymphomas","Osteosarcoma"],"catalyst":""},{"name":"ATRA","genericName":"ATRA","slug":"atra","phase":"marketed","mechanism":"ATRA (all-trans retinoic acid) promotes differentiation of acute promyelocytic leukemia cells and induces apoptosis by binding to retinoic acid receptors.","indications":["Acute promyelocytic leukemia (APL)"],"catalyst":""},{"name":"RIF","genericName":"RIF","slug":"rif","phase":"marketed","mechanism":"RIF is a rifampicin-based antimicrobial agent used in pediatric leukemia supportive care to prevent or treat infections.","indications":["Infection prophylaxis and treatment in pediatric leukemia patients"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2025-01-24","type":"regulatory","source":"Journal of Hematology Oncology Pharmacy","summary":"Effects of Levofloxacin Prophylaxis in Pediatric Patients With Acute Myeloid Leukemia, Relapsed Acute Lymphoblastic Leukemia, or Patients Undergoing Hematopoietic Stem Cell Transplant - Journal of Hem","headline":"Effects of Levofloxacin Prophylaxis in Pediatric Patients With Acute Myeloid Leukemia, Relapsed Acute Lymphoblastic Leuk","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBuQUZzV0N0UEloaGJuZWtES3ZGaWFWRkx4VWJvTWx4Z05sek9HdFhfVEVHSWhUcFdxenlBeXQ0Q2diM3FUWGRyMTdnRm1IU3V2Snl3NGw3QXZFMjJjbUZV?oc=5","date":"2023-11-25","type":"trial","source":"Nature","summary":"Prognostic implications of CD9 in childhood acute lymphoblastic leukemia: insights from a nationwide multicenter study in China - Nature","headline":"Prognostic implications of CD9 in childhood acute lymphoblastic leukemia: insights from a nationwide multicenter study i","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxOY2ZuQXZOdkk2M1lYRk4tYVg4M1dNY3dwMXBVOGtVdmRPT1RjWk1hdjRzUklfVmllajNGS0lhRVZzeTdXREtfWUQwdV9PMmJlQkNUR0ZmdEhyWHQxdnhrcU9Qa3o2aDlkTWY3dERzTW44VE9LYnBUdkxxWUd6M2hfOWtQZDRRRFlic0V0cllISzZuR0lOUVFyS3lwY2xBVHVnOXBBWFpNaGRvM0dOYXZLWENyTVFDQ29nNC1mWA?oc=5","date":"2023-01-25","type":"pipeline","source":"TBIJ","summary":"The drug was meant to save children’s lives. Instead, they’re dying. - TBIJ","headline":"The drug was meant to save children’s lives. Instead, they’re dying.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxNcU5VLXFVeEs0cVk5cHpFTGxhRDNYRnppekgzVkJ0TlFOUmxIU3Q2czUtbkVfSmM5YmctMWdXenQtOFp4ZDZ0RnItMTZkUXVoTGw3eUhocEd2ZGJBN2hDMnZOQ1doQzBmSF9fZlMxM2xnbDBDZHRBMGVRMmFHM2VhOUlrSXFLRG1fU2VHN2E0cFdjUjQ2RHQzeWYwbkNRT1R2TGpBdl8xVzlQejlNYVFZNkNUalpSTTJVWldV?oc=5","date":"2018-09-28","type":"regulatory","source":"Caixin Global","summary":"Novartis Bets on Beijing Approving Cutting-Edge Cancer Treatment - Caixin Global","headline":"Novartis Bets on Beijing Approving Cutting-Edge Cancer Treatment","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxQdlRiUDQ0Q1l1SG5yWUsyeXozNkdSTml2SWRIamhaMU0wQ1VyWUFTb3Jsd05GczFiYnQ5WVBrVjZ0RXgzSHlYOGtXMncxQ0N0Szl6QkJya0JMTUVteXFWcDNLSUkzb0tkNjFKb1hrR3I1X2FNS3UxemhDcE1lRFoyZU83N1paSmtsVWNhSWpmY01BU21yTXE5a2k1UUdBZGx0U2lHQzhWbkktUUM4azlLSGFn?oc=5","date":"2017-12-06","type":"pipeline","source":"grandviewresearch.com","summary":"Acute Lymphocytic Leukemia Therapeutics Market Report, 2030 - grandviewresearch.com","headline":"Acute Lymphocytic Leukemia Therapeutics Market Report, 2030","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"marketed":5},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}